Brazilian and Paraguayan Health Agencies Warn of Risks from Counterfeit Weight Loss Pens
Health authorities in Brazil and Paraguay are sounding the alarm over the increasing availability of counterfeit weight loss medications, often marketed as injectable “skinny pens,” and the serious health risks associated with their use. The growing problem has prompted increased scrutiny and enforcement actions on both sides of the border.
On January 21, 2026, Brazil’s National Health Surveillance Agency (Anvisa) issued a resolution prohibiting the commercialization, manufacturing, importation, and use of these unregulated weight loss injections originating from Paraguay. This decision targets brands gaining popularity on social media platforms but operating outside of legal channels. The move underscores the potential dangers of seeking quick weight loss solutions without medical supervision.
Paraguay’s National Directorate of Health Surveillance (Dinavisa) first acknowledged the illegal trade of counterfeit weight loss pens along the border with Brazil on December 24, 2025, and released a public health alert. Dinavisa classified the situation as a “grave risk to public health,” citing concerns about falsified pens intended for the treatment of obesity and diabetes. This acknowledgment prompted similar concerns among Brazilian authorities.
Anvisa issued its own alert on February 10, 2026, warning against the use of these pens without medical supervision and for conditions not approved in the medication’s labeling. The agency noted that many consumers are purchasing these products from vendors bringing them across the border from Paraguay, often at lower prices and without the need for a prescription or specialized medical follow-up. This lack of oversight is a key concern for health officials.
The illicit trade has become increasingly sophisticated, with vendors attempting to evade border controls by concealing the pens in various locations, including car upholstery, false compartments, and even inside tires. This makes detection and prevention a significant challenge.
As of February 10, 2026, authorities are monitoring 65 suspected deaths potentially linked to the use of these weight loss pens. The potential for serious adverse effects, including pancreatitis, highlights the dangers of using unregulated medications.
Health officials are urging the public to avoid purchasing or using these products and to consult with a healthcare professional for safe and effective weight management strategies. The increased vigilance from both Anvisa and Dinavisa aims to curb the illegal trade and protect public health.
On January 26, 2026, reports indicated that the risks associated with the “skinny pens” from Paraguay are prompting increased scrutiny and prohibition by Anvisa.
In Passo Fundo, Brazil, the Sanitary Surveillance agency has intensified its monitoring of the irregular sale of these “skinny pens.”
